Fund moves
113 tracked managers disclosed the same change for Q2 2026. From a 13F filed Jul 17, 2026 covering holdings at Jun 30, 2026 — a quarter-end snapshot, not a live trade.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Traded May 7, 2026 · Filed Jun 18, 2026
An Abbott Laboratories director paid $174K out of pocket for Abbott Laboratories shares. 2 other people at Abbott Laboratories bought some too, in the same month. Shares held went up 9% with this purchase.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell.
open market purchase
Code P — open-market or private purchase
~$173,640
Shares × reported transaction price
$100K–$500K
+9.4%
Purchase shares ÷ estimated pre-transaction holdings, from the filing
Not enough history to judge
Confirmed open-market purchases by the same insider in the available history
3 distinct insiders in 30 days
Distinct insiders at the same issuer with confirmed open-market purchases
21 days after results of Apr 16, 2026, 70 days before results of Jul 16, 2026
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
Closed at $87.01 on May 7, 2026, within 1% of its 52-week low, after a 17% drop over the previous 30 trading days
52-week range $86.30 (May 6, 2026) to $138.08 (Jun 24, 2025), 1% of the way up, from 251 adjusted closes. 30 trading days earlier: $104.83 on Mar 25, 2026. Describes the past only, not a forecast
RSI 26, 27% under its 200-day average, 15% under its 50-day average, 37% below the 52-week high, 20-day volatility 31% a year, against the S&P 500: −24 points over 1 month, −28 points over 3 months, −39 points over 6 months
From the adjusted closes up to May 7, 2026. RSI: Wilder's 14-day relative strength index (0 to 100). Averages: the last 50 and 200 closes. Volatility: standard deviation of the last 20 daily returns, annualised. S&P 500: the stock's move minus SPY's between the same dates (21, 63 and 126 trading days). Describes the past only, not a forecast
None found in footnotes
Only flagged when a footnote says so; never inferred
John G Stratton's largest purchase of ABT in their filings since 2019. John G Stratton's first purchase of ABT since Jan 2019
Compared with every open-market purchase and sale of this company in SEC filings since 2006. A fact about the record, not a signal to trade
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | +5.6% | −0.5% | +6.0% |
| 30 days | +14.5% | +0.4% | +14.1% |
| 90 days | +17.3% | +3.9% | +13.3% |
Past results only. Not a forecast.
Fund moves
113 tracked managers disclosed the same change for Q2 2026. From a 13F filed Jul 17, 2026 covering holdings at Jun 30, 2026 — a quarter-end snapshot, not a live trade.
Fund moves
113 tracked managers disclosed the same change for Q2 2026. From a 13F filed Jul 17, 2026 covering holdings at Jun 30, 2026 — a quarter-end snapshot, not a live trade.
Fund moves
113 tracked managers disclosed the same change for Q2 2026. From a 13F filed Jul 16, 2026 covering holdings at Jun 30, 2026 — a quarter-end snapshot, not a live trade.
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.